294 related articles for article (PubMed ID: 18716986)
1. [Prophylactic mastectomy in women at high risk for breast cancer: indications and options].
Scheufler O; Fritschen Uv
Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):239-47. PubMed ID: 18716986
[TBL] [Abstract][Full Text] [Related]
2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer treatment in mutation carriers: surgical treatment.
Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
[TBL] [Abstract][Full Text] [Related]
4. Satisfaction with breast reconstruction in women with bilateral prophylactic mastectomy: a descriptive study.
Metcalfe KA; Semple JL; Narod SA
Plast Reconstr Surg; 2004 Aug; 114(2):360-6. PubMed ID: 15277800
[TBL] [Abstract][Full Text] [Related]
5. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
6. Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
This P; de la Rochefordière A; Savignoni A; Falcou MC; Tardivon A; Thibault F; Alran S; Fourchotte V; Fitoussi A; Couturaud B; Dolbeault S; Salmon RJ; Sigal-Zafrani B; Asselain B; Stoppa-Lyonnet D;
Fam Cancer; 2012 Sep; 11(3):473-82. PubMed ID: 22711610
[TBL] [Abstract][Full Text] [Related]
7. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
[No Abstract] [Full Text] [Related]
8. The Preventive Intervention of Hereditary Breast Cancer.
Cao A; Huang L; Shao Z
Adv Exp Med Biol; 2017; 1026():41-57. PubMed ID: 29282679
[TBL] [Abstract][Full Text] [Related]
9. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
10. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
Sigal BM; Munoz DF; Kurian AW; Plevritis SK
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1066-77. PubMed ID: 22556274
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Heemskerk-Gerritsen BA; Brekelmans CT; Menke-Pluymers MB; van Geel AN; Tilanus-Linthorst MM; Bartels CC; Tan M; Meijers-Heijboer HE; Klijn JG; Seynaeve C
Ann Surg Oncol; 2007 Dec; 14(12):3335-44. PubMed ID: 17541692
[TBL] [Abstract][Full Text] [Related]
12. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
[TBL] [Abstract][Full Text] [Related]
13. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Domchek SM; Rebbeck TR
LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
[TBL] [Abstract][Full Text] [Related]
14. A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap.
Hunsinger V; Marchac AC; Derder M; Hivelin M; Lecuru F; Bats AS; Lantieri L
Ann Chir Plast Esthet; 2016 Jun; 61(3):177-82. PubMed ID: 26946931
[TBL] [Abstract][Full Text] [Related]
15. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
16. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
[TBL] [Abstract][Full Text] [Related]
17. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
[TBL] [Abstract][Full Text] [Related]
18. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
19. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
Skytte AB; Gerdes AM; Andersen MK; Sunde L; Brøndum-Nielsen K; Waldstrøm M; Kølvraa S; Crüger D
Clin Genet; 2010 Apr; 77(4):342-9. PubMed ID: 20059483
[TBL] [Abstract][Full Text] [Related]
20. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
